Loading...
WCLC congresses2023-11-21T10:44:35+01:00

WCLC 2023 – Singapore

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from WCLC 2023

WCLC 2023 English

Full report (english)

EXPERT VIDEOS

All video interviews from WCLC 2023

In this exclusive video interview Paul Van Schil, the current president-elect of the IASLC, provides insights into projects that will be at the focus of the IASLC in the near future and explains notable challenges regarding collaborative science and global education, which are part of the IASLC’s strategic plan. Furthermore, he shares his thoughts on improving accessibility to multidisciplinary care at the global level, the optimal first-line therapy for patients with pleural mesothelioma and his personal highlights from the WCLC 2023 congress.

Yasushi Goto discusses the effects of delta-like ligand 3 (DLL3) expression status on clinical outcomes in treated patients with small-cell lung cancer, explains in which ways DLL3 can be used as a direct target for treatment and highlights the challenges and future perspectives regarding DLL3-directed therapies in patients with SCLC. Lastly, he shares his thoughts on the optimal first-line therapy for patients with pleural mesothelioma.

WCLC 2022 – hybrid, Vienna

 

Lecture Board: Maximilian Hochmair, MD; Michael Thomas, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from WCLC 2022

WCLC 2022 English

Full report (english)

EXPERT VIDEOS

All video interviews from WCLC 2022

Filiz Oezkan depicts the most important factors influencing the choice of treatment in patients with PD-L1-positive NSCLC, explains how the 50 % PD-L1 threshold affects the treatment selection and explains which treatment options appear favorable in the setting of PD-L1 levels below 1 % while also taking into account possible challenges associated with biomarker testing for PD-L1 in NSCLC.

Alexander Louie explains which modes of imaging can be particularly helpful when clinicians face unique diagnostic challenges in lung cancer patients with pneumonitis after chemoradiotherapy and immunotherapy. Moreover, he summarizes what needs to be considered regarding pneumonitis treatment and highlights current and future pneumonitis research areas.

Maximilian Hochmair highlights relevant study data in the field of EGFR-mutated advanced lung cancer, novel therapies in the management of KRAS p.G12C mutation as well as MET exon 14 skipping mutations in NSCLC. He draws attention to antibody drug conjugates in the management of NSCLC patients as well as the optimal treatment sequence in the ALK-positive setting.

Federico Cappuzzo discusses the effectiveness and limitations of minimal residual disease (MRD) assessment in the detection of patients with early-stage lung cancer at low risk of relapse and highlights which clinical investigations regarding the clinical impact of MRD assessments in solid tumors are ongoing and what we can expect from them in the future.

Helmut Popper talks about the characteristics of the recently defined molecular subtypes of small-cell lung cancer (SCLC), outlines if this subtyping is suitable for therapeutic decision-making and gives an overview about potential new therapeutic targets in the field of SCLC.

Julia Rotow summarizes the achievements of EGFR tyrosine kinase inhibitors in the neoadjuvant therapy of lung cancer regarding multiple clinical outcomes, discusses if modification of the disease biology will be a feasible treatment goal in the setting of EGFR-directed neoadjuvant treatment sometime and talks about the individualization of neoadjuvant treatment of oncogene-driven lung cancer.

WCLC 2020 – virtual

Lecture Board: Maximilian Hochmair, MD; Luis M. Montuenga, PhD; Ross Soo, MB BS, PhD; Alexander Spira, MD, PhD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from WCLC 2020

WCLC 2020 English

Full report (english)

WCLC 2020 Mandarin

Full report (mandarin)

WCLC 2020 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2020

Luis M. Montuenga talks about factors that are impeding the implementation of lowdose computed tomography lung cancer screening at the global level and describes biomarkers/molecular technologies that are promising with respect to early detection of lung cancer. Moreover, he summarizes advantages and drawbacks of pan-cancer ctDNA analysis in liquid biopsy.

Alex Spira highlights the advantages, shortcomings and the future potential of antibodydrug conjugates, the balance between proand anti-inflammatory cytokines within the tumor microenvironment, and the preclinical evidence for targeting inflammatory cytokines in advanced or metastatic non-smallcell lung cancer.

Ming Tsao relates to the innovations of the 5th edition of the WHO classification of lung tumors in terms of additional chapters, new tumor types and grading systems. Additionally, he discusses the use of organoids as potential platforms for drug testing and biomarker validation, as well as miRNAs for early lung cancer detection.

WCLC 2018 – Toronto

Lecture Board: Heidi A. Hamann, PhD; Vera Hirsh, MD; Maximilian Hochmair, MD; Herbert Ho Fung Loong, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from WCLC 2018

WCLC 2018 English

Full report (english)

WCLC 2018 Mandarin

Full report (mandarin)

WCLC 2018 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2018

Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using <em>EGFR</em>-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

This is the first study in more than 20 years to show a clinically meaningful survival improvement over the current first-line standard of care in this setting. A singular survival benefit has also been obtained with durvalumab in unresectable, stage III non–small-cell lung cancer.

Vera Hirsh • MD, Department of Oncology, McGill University Health Center, Montreal, Canada

WCLC 2017 – Yokohama

Lecture Board: John Edwards, MB,ChB,PhD; Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from WCLC 2017

WCLC 2017 English

Full report (english)

WCLC 2017 Mandarin

Full report (mandarin)

WCLC 2017 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2017

David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

Paul A. Bunn discusses current and future treatment options in lung cancer.

Clinical trials conducted in Asia have contributed considerably to the development of targeted therapies, such as EGFR or ALK tyrosine kinase inhibitors, and immunotherapies, but also to the implementation of cytotoxic drugs. Particularly in lung cancer, Eastern Asia has evolved into a stronghold of cancer research over the previous years.

Fred R. Hirsch • MD • PhD, Dep. of Pneumology, Hopitaux Universitaires de Strasbourg

WCLC 2016 – Vienna

Lecture Board: David P. Carbone, MD, PhD; Maximilian Hochmair, MD; Martin Filipits, MD; Anders Mellemgaard, MD, PhD; Remón Rami-Porta, MD; Benjamin Solomon, MBBD, PhD; Johan Vansteenkiste, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from WCLC 2016

WCLC 2016 English

Full report (english)

WCLC 2016 Spanish

Full report (spanish)

WCLC 2016 Mandarin

Full report (mandarin)

WCLC 2016 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2016

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

James Chih-Hsin Yang talks TKIs

The international nature of the IASLC and the pace of progress in the field of lung cancer have prompted us to move annual world conferences, as well as annual regional meetings. We are hoping to make the IASLC WCLC the established platform for the interdisciplinary, international dissemination of the state of the art in lung cancer research.

David P. Carbone • MD • Phd, Dep. of Pneumology, Hopitaux Universitaires de Strasbourg
Go to Top